This study involves the structural and functional properties of the recombinant melanocortin 4 receptor (MC 4 R) expressed in the HEK-293 cell line. Using co-immuno-purification approaches, the receptor appears to be an oligomer, which can be crosslinked through disulphide bonds involving a native cysteine residue (84) to give a dimeric species. This position is located near the cytosolic region of transmembrane segment 2 and it is suggested that this is an interacting interface between MC 4 R monomers. Using co-expression of the native protein and a C84A mutant, it appears that the receptor also forms higher order oligomers via alternative interfaces. Interestingly, disulphide crosslink formation does not occur if the receptor is uncoupled from its G-protein, even though the oligomeric state is preserved. This suggests that the conformational changes, which occur on activation, affect the TM2 interface. The pharmacology of the agonist, NDP-MSH, indicates that the MC 4 R retains high affinity for the ligand in the absence of the G-protein but occupancy for the ligand is increased. The data can be interpreted to suggest that the G-protein exerts a negative allosteric effect on the receptor. Co-expression of one receptor lacking the ability to signal with another, which cannot bind the agonist, restored ligand-dependent activation of the G-protein to situations in which neither receptor on its own could activate the G-protein. Such transactivation suggests meaningful cross talk between the receptor subunits in the oligomeric complex. These studies demonstrate further unique features of the MC 4 R.
Introduction
The MC 4 R belongs to Family A of the G-protein coupled receptors (GPCRs) and is conventionally activated by peptide agonists inducing coupling to Gα s , although not exclusively [1] . The receptor is located primarily in the brain and shown to have an important regulatory role in energy homeostasis and food intake [2] [3] [4] . It is, therefore, a potential therapeutic target for a variety of conditions including anorexia and obesity [5] . Understanding its functionality may be the key to successfully exploiting the receptor as a druggable target. MC 4 R possesses unique structural features not seen in other Family A members. These include some highly conserved key residues in TM regions which have been substituted including; Pro 4.59, 5 .50 residues at TM4
and TM5 respectively and the Cys 3.25 residue located in the extracellular portion of TM3 which generally forms a disulphide bond to a Cys residue in ECL2. The Family A conserved Cys 3.25 residue is substituted in the MC 4 R by Asp 3.25 (Asp122) which plays a key role in interacting with the agonist peptides [6] [7] [8] . The atypically small ECL2 lacks the second conserved Cys residue in the disulphide bond, the Asp189 in its place also being critical for agonist binding [6] [7] [8] .
The MC 4 R endogenous agonists are the melanocortin peptide which contains a conserved tetrapeptide sequence His-Phe-Arg-Trp- [9, 10] and the pharmacological tool, NDP-MSH, developed from the endogenous peptide α-MSH, whereby the essential Phe 7 in the tetrapeptide sequence is replaced with D-Phe 7 to give an agonist of increased potency [9, 10] . Not only is MC 4 R structurally disparate from other Family A GPCRs but the receptor is also unusual in that it also has a native antagonist, the 132 residue agouti related protein (AgRP) which is expressed in the neurones of the arcuate nucleus of the hypothalamus [11] . It has been shown to lower constitutive levels of cAMP [12] [13] [14] .
It is well reported, though still not universally accepted, that many GPCRs appear to form homo-and hetero-dimers. The research emphasis now has shifted to the structural characteristics and functional significance of oligomeric states. Several roles for dimerization have been suggested but there are no consistent commonalities amongst families [15, 16] . Conventionally, it is thought that one receptor sub-unit promotes GDP-GTP exchange on one G-protein. However , it has been proposed that one receptor molecule may not be sterically able to provide simultaneous interaction with all the G-protein subunits (both Gα and Gβγ) [17] . This raises the possibility of trans-activation between subunits in a complex and the potential for discrete signaling pathways [18, 19] .
Several TM domain interfaces have been predicted for Family A receptors, including TM4 and TM5 in rhodopsin [20, 21] and in the D 2 dopamine receptor [22] [23] [24] [25] . Further to this, by employing a bioinformatics and molecular modeling approach to current available data, Simpson et al., have implicated TM4 to have a key role in dimerization across family A GPCR's [26] . Cysteine mutagenesis and cross-linking studies with the D 2 dopamine receptor have discriminated between the "active" R* state (agonist bound) conformation [24] represented by a TM4 only interface and the "inactive" R state (inverse agonist bound) conformation, demonstrating TM4 and possible TM5 involvement [20, 21] . In rhodopsin, through disulphide bond formation at helix 8, Cys316 was implicated as a contact site in the homo-dimer [27] . Recent crystal structure of the dimeric μ-opioid receptor bound to the antagonist morpinan, has shown TM6-TM5 and TM1-TM2-H8 as potential interface regions [28] . Finally, a recent exploration of ligand bias has re-examined the possibility of oligomerization and multiple conformation involvement in G-protein directed signaling [18] .
There is evidence from enzyme linked immunosorbent assays and fluorescence energy transfer studies [29] to suggest that MC 4 R assembles as a homo-dimer, but the sites of interaction and the functional significance are slightly understood [29, 30] . Additionally, binding kinetics for the agonist, NDP-MSH, has suggested a tandemly-arranged binding site across the homo-dimer [31, 32] . Dominant negative mutations of the MC 4 R including D90N and S136P have been used to model interaction between dimers that stabilize the TM helical arrangement. These data suggest that TM2, TM3 and TM7 are important in the dimeric complex [33] and raise the possibility of multi-activated states and differential G-protein coupling which result in biased agonistic action [34] .
Here, we characterize the oligomeric form of the MC 4 R, including the identification of one of its contact sites, the presence of higher order oligomeric species and the novel involvement of the G-protein in conformational rearrangements. We have also explored co-operative behavior between the receptor and the G-protein and between individual protein subunits.
Materials and methods

Materials
The expression vector, pcDNA3, containing cDNA for the human wild type (WT)-MC 4 
Amino-terminal tagging
The HA (YPYDVPDYA) and c-Myc (EQKLISERDL) N-terminally tagged WT-MC 4 R was generated using the polymerase chain reaction (PCR). The sequence contained a Hind III restriction site. A BamH I restriction site was incorporated into the 3′-carboxyl terminus primer at the stop codon. The constructs were sub-cloned into pcDNA3 vector and pcDNA3.1 Hygromycin©.
Mutagenesis
Point mutations were introduced into the WT-MC 4 R sequence using the QuikChange® Site-Directed Mutagenesis Kit (Stratagene) with the MC 4 R-pcDNA3 vector and c-Myc-MC 4 R-pcDNA3.1 Hygromycin© as template.
HEK-293 cell transfection
HEK-293 cells were passaged 24 h prior to transfection, and seeded at 70% confluency. On the day of transfection, 6.5 μg/ml of DNA was added to serum-free DMEM with 2% of Plus reagent (Invitrogen) and 1.25% of Lipofectamine™ (Invitrogen) according to the manufacturer's instructions. The reaction was terminated by the replacement of the media with complete DMEM. Two days after transfection, cells were harvested using 0.02% EDTA in PBS, and pelleted by centrifugation at 4000 rpm for 5 min (Hettich, Rotofix 32, swingout rotor). The cell pellets were washed twice with PBS (Dulbecco's) and re-suspended in an appropriate solution according to the investigation to be carried out. Alternatively, cells were harvested for propagation of stable transformants in the appropriate selection media, depending on single or dual transfection. If dual transfection occurred, both pcDNA3 and pcDNA3.1 Hygromycin© were utilized simultaneously during DNA/ Lipofectamine™ complex formation.
Cell growth
HEK-293 cells were routinely maintained in DMEM medium supplemented with 10% fetal calf serum, 100 μg/ml penicillin, 100 μg/ml streptomycin and Glutamax™ (Invitrogen). Stably transfected cells were grown in the same medium supplemented with 800 μg/ml Geneticin G418 sulfate or/and 200 μg/ml Hygromycin. Cells were grown at 37°C in 5% CO 2 .
Membrane preparation
Cell membranes were prepared from cells grown as a monolayer to confluency. The growth medium was removed and the cells were washed three times with 10 ml cold PBS. The cells were then treated with 0.02% EDTA solution for 15 min, harvested, and centrifuged at 5000 rpm for 5 min. The cell pellet was re-suspended in assay buffer (25 mM HEPES-KOH, 1.5 mM CaCl 2 1 mM MgSO 4 100 mM NaCl, and pH 7.0 plus protease inhibitors), and homogenized using a teflon/glass homogenizer. The homogenate was then centrifuged for 10 min at 31000 rpm, at 4°C. The supernatant was discarded and the pellet was re-homogenized in assay buffer and centrifuged as before. Finally, the supernatant discarded the pellets homogenized in 25 mM HEPES-KOH (pH 7.0), containing 10% sucrose and the membranes frozen at −70°C.
Cross-linking
Membranes (50 μg of protein) were diluted to a concentration of 25 μg/ml with binding buffer (25 mM HEPES-KOH, 1.5 mM CaCl 2 , 1 mM MgSO 4 , 100 mM NaCl, and pH 7.0 plus protease inhibitors). Cross-linking was induced using 5 mM copper 1-10 phenanthroline (CuP) at 22°C for 1 h. The reaction was terminated by addition of 5 times SDS sample buffer (60 mM Tris-HCl, pH 6.8, 2% SDS, and 10% glycerol) containing 25 mM N-ethyl maleimide (NEM) to react with any free sulfhydryl groups.
Co-immuno-purification
1000 μg of CuP treated membranes expressing HA-and c-Myc tagged WT-MC 4 R were incubated with 3:1 ratio of immunopurification buffer (25 mM HEPES-KOH, 1.5 mM CaCl 2, 1 mM MgSO 4, 100 mM NaCl, 1% Triton-X, and pH 7.0 plus protease inhibitors). 100 μl of Anti-c-Myc protein G-conjugated beads was added overnight at 22°C, after which, the beads were washed with 0.5 ml of immunopurification buffer, and centrifuged (12,000 g) for 2 min. The supernatant was discarded and the wash step was repeated 10 times. Finally the Protein G bound complex was incubated with 25 μl of SDS-PAGE sample buffer (62.5 mM Tris/HCl pH 6.8, 2% SDS, 5% sucrose and 0.009% bromo blue) without β-mercaptoethanol, for 30 min at 37°C. The samples were centrifuged and the supernatants were collected. This was repeated twice and the supernatants were pooled. The samples were resolved by 12.5% SDS-PAGE, and Western blotting was carried out with antibodies to the HA epitope.
Immunoblotting
Proteins were resolved on a 12.5% SDS-PAGE gel and electroblotted on to polyvinylidinedifluoride (PVDF) membranes (Fluoro Trans r ). The membrane was blocked for 1 h at room temperature with Super Block in PBS (Roche Molecular Biochemicals). The MC 4 R was identified using anti-HA-HRP (Sigma) to the N-terminal tag at a dilution of 1:1000, and antibody AB5134 (Chemicon international) was raised to the rat MC 4 R at a 1:1000 dilution in antibody buffer (PBS plus 10% BSA). Immuno-reactivity was determined with anti-rabbit horseradish peroxidase-conjugated antibody (Amersham Bioscience) in antibody dilution buffer (1:5000) by Chemiluminescence (Roche Molecular Biochemicals). (2000-6000 cpm counts for total binding respectively). Several known concentrations of equivalent ligand were allowed to compete for the radio-ligand in a volume of 100 μl. The mixture was incubated for 45 min at room temperature. The reaction was stopped by filtration through 0.5% polyethyleneimine and 1 mg/ml BSA pre-treated filters and washed with 200 μl ice-cold PBS. Non-specific binding was measured using 1 μM SHU9119.
Radio-ligand binding assays
Cyclic AMP response (CRE)-luciferase assay
24 h post-transfection, HEK-293 CRE-luc cells were plated into 96 well blackwall, clear bottom, and poly-D-lysine coated microplates (Corning Costar) at a density of 50,000 cells/well and cultured for a further 12-18 h. Media were replaced with 100 μl phenol-red-free culture medium including IBMX and the appropriate concentration of agonist NDP-MSH. [35] . The microtitre plates were incubated for 4 h at 37°C after which Luclite® reagent (Perkin Elmer) was added to each well, the plates were sealed and subjected to dark adaptation for 5 min at room temperature. Luciferase activity was determined by luminescence using NOVAstar (BMG).
Data analysis
All measurements, except where stated otherwise, were carried out in triplicate in three independent experiments. The values quoted and depicted graphically are the means of the independent determinations with the corresponding SEM. In competition binding studies, counts were normalized to the maximum and non-specific binding within each data set and the pIC 50 ] [37] . The significance of differences between values was determined by comparing mean values using two tailed unpaired or paired Student's t test.
Results
Identification of a wild type MC 4 R homodimer
Membranes prepared from HEK-293 cells stably transfected with both HA and c-Myc tagged forms of the cloned human WT-MC 4 R, were isolated, solubilized in mild detergent and subjected to immunopurification using immobilized anti-c-Myc antibody. The bead-retained fraction was solubilized with SDS and subjected to PAGE, followed by Western blotting using an anti-HA antibody. This revealed a clear band migrating with a mass equivalent to 36 kDa (Fig. 1 ), identical to that seen using antibody to the wild-type receptor or to the c-Myc tag. The same result was obtained when membranes were incubated with 1 mM GTPγS (binds irreversibly to the G-protein, uncoupling it from the receptor) plus 0.5 mM NDP-MSH prior to solubilization and immuno-purification (Fig. 1 ). This suggests that MC 4 R is a stable dimer, in the plasma membrane with and without the G-protein or the ligand.
Solubilization and mixing of membranes from cell-lines expressing either HA-WT-MC 4 R or c-Myc-WT-MC 4 R, prior to immuno-purification and Western blotting as above, demonstrated that no aggregation of the HA-with the c-Myc-tagged protein occurred during solubilization and incubation ( Fig. 1) , reinforcing the formation of stable dimers in the intact cell.
Further controls included immuno-purification of the dimeric form of the receptor under different detergent conditions (n-dodecyl-beta-D-maltoside and n-octylglucoside) to exclude any possibility of receptor co-location in triton-resistant lipid domains.
Homologous binding studies using either the agonist [ 4 R indicated that addition of the tags had no effect on the functional properties of the receptor (Table 1) .
Cross-linking the dimeric MC 4 R complex
Membranes prepared from HEK-293 cells stably expressing the WT-MC 4 R were incubated for 1 h at room temperature without and with 5 mM CuP (Fig. 2) , washed, solubilized in mild detergent and subjected to SDS-PAGE under reducing and non-reducing conditions. Subsequent Western blotting with a polyclonal antibody to the MC 4 R (Chemicon, AB5236) revealed a band at 70 kDa, in those samples treated with CuP and run under non-reducing conditions. In the absence of CuP only the 36 kDa monomeric receptor is seen (the 40 kDa species is non-specific labeling seen also in the non-transfected cells). The oligomer dissociated under reducing condition confirming the formation of a disulphide bond. Disulphide bond formation occurred in a timedependent manner and was essentially complete within 30 min with 5 mM CuP at 4°C.
Identification of residues involved in cross-linking
There are 15 Cys residues in MC 4 R. Site-directed mutagenesis was used to introduce single Ala mutations at all these positions (Table 2) . A double mutant (C318A, C319A) was also produced. All the mutants except C84A-MC 4 R retained the ability to form a disulphide bond ( 
Conformation of the cross-linked homodimer and identification of higher order oligomers
Further co-immuno-purification studies were carried out using membranes from cells expressing both c-Myc-WT-MC 4 R and HA-WT-MC 4 R. Following treatment with 5 mM CuP, the dimeric species at 70 kDa can be confirmed as a homo-meric complex, purifying with anti-c-Myc and blotting with anti-HA (Fig. 4) .
When similar immuno-purification studies were performed on membranes expressing HA-WT-MC 4 R with c-Myc-C84A-MC 4 R and subjected to CuP treatment, followed by SDS-PAGE in the absence of reducing agent, the covalent dimeric band was seen following purification via the c-Myc epitope and blotting with the anti-HA antibody (Fig. 4) . Since the C84A mutant cannot form covalent dimers (Fig. 3) , this implies that cross-linked complex is the HA-WT-MC 4 R and must have become associated in-situ with the c-Myc-C84A-MC 4 R mutant to enable co-immuno-purification with the anti-cMyc antibody, thereby providing evidence for higher order oligomerization.
When immuno-purification via the c-Myc epitope was performed with both the c-Myc-WT-MC 4 R/HA-WT-MC 4 R and c-Myc-C84A-MC 4 R/HA-WT-MC 4 R dual expressed membranes in the absence of CuP, the 36 kDa band blotted with the anti-HA antibody in both cases, indicative of a stable complex in mild detergent.
The significance of uncoupling the G-protein
The nucleotide GTPγS is known to bind to the Gα sub-unit, uncoupling the G-protein from the receptor [38] . Membranes were incubated at room temperature for 30 min with GTPγS at various concentrations from 100 nM to 1 mM in the presence of 0.5 mM NDP-MSH. Western blot analysis (Fig. 5) indicated that 1 mM GTPγS after 30 min completely prevented covalent dimerization on subsequent treatment with CuP.
Immuno-purification studies with membranes treated with 1 mM of GTPγS, demonstrated that although the receptor could no longer be covalently cross-linked, the dimer still existed (Fig. 1 ). The Gα s -protein purifies with the dimeric form of the receptor but not in the presence of , via a covalent bond, which was reduced by the addition of βME (lane 4). Untreated membranes were also subjected to βME to reduce any internal disulphide bonds (lane 2). (Panel B) It demonstrates that the band at 40 kDa is present when HEK-293 cells are not transfected with MC4R, and therefore is non-specific. The experiment was repeated on at 4 independent occasions. Molecular mass is indicated as kDa.
1 mM GTPγS (data not shown). The level of Gα s -protein association to the MC 4 R is reduced dose dependently with GTPγS (Fig. 6 ). The two condition-covalent crosslinking and G-protein association are inversely correlated and presumably reflect a subtle conformational difference, affecting this region of the receptor.
In further studies to examine the concentration-dependent effect of GTPγS on Gα s coupling, membranes (expressing both HA-WT-MC 4 R and cMyc-WT-MC 4 R) were treated with increasing concentration of GTPγS (1 μM-1 mM) for 30 min and the receptor immuno-purified using the c-Myc epitope. Western blotting of Gα s and the HA epitope of the MC 4 R, demonstrated a concentration-dependent decrease in Gα association with the MC 4 R in the presence of 1 μM to 1 mM GTPγS, but there was no change in the levels of the MC 4 R on immunopurification (Fig. 6) .
Analysis of the affinity of the receptor for both the agonist and antagonist in the presence of 1 mM GTPγS indicated that the pK d for SHU9119 was unaltered (8.32 vs. 8.21, without and with 1 mM GTPγS respectively) (Fig. 7a) , while the pK d for the agonist was shifted slightly to the right, (7.98 ±0.01 to 7.44 ±0.11 for NDP-MSH without and with 1 mM GTPγS respectively). This is validated by historic data where only a 3-fold change in the K d occurred in the presence of 30 μM GTPγS [6, 39] .
Further experiments were carried out at increasing concentrations of GTPγS with 0.2 nM [
125 I] NDP-MSH (Fig. 7b) (Fig. 7b) . From 1 μM to 1 mM GTPγS, the percentage specific-binding roughly doubled for the agonist. Interestingly, this increase correlated with inhibition of cross-linking of the receptor in the presence of GTPγS as assessed by Western blotting and densitometry. The pEC 50 for GTPγS on NDP-MSH binding was 4.22 ± 0.21 μM, which is not significantly different (*p b 0.05, paired t test) to the effect on the percentage cross-linking inhibition (increase of monomer formation), which was 4.14 ± 0.23.
Additionally, the B max values calculated from competition curves without and with 1 mM GTPγS for NDP-MSH were 746 ± 43 fmol/mg and 3532 ± 688 fmol/mg*, respectively and for SHU9119 1452 ± 384 fmol/mg and 1725± 89.8 fmol/mg, respectively. The B max for the agonist NDP-MSH, increased significantly~4 fold (*p b 0.05, unpaired t test), which is similar to the increase in specific binding of NDP-MSH in the presence of the equivalent concentration of GTPγS (Fig. 7b) . Other nucleotides used in the same concentrations also induced an effect on the level of B max , for example Gpp(NH)p by a similar level to GTPγS, GTP to a lesser extent, and ATP and GDP less still.
Trans-activation within the MC 4 R oligomeric complex
In order to examine the possibility of trans-activation, a series of experiments were carried out utilizing receptors lacking either the ability to activate or to interact with the agonist NDP-MSH. The first receptor characterized was c-Myc-C318A-MC 4 R, bearing a mutation at a potential palmitoylation site located on the C-terminal region of the receptor. This mutant is interesting because it cannot be activated (Table 3) but the binding affinity of this receptor for the agonist NDP-MSH was only slightly shifted to the right by approximately~3.5-fold compared to the c-Myc-WT-MC 4 R (pK d = 7.05 ±0.35 vs 7.60 ±0.19) while the pK d for the antagonist SHU9119 was unaltered. This profile is reminiscent to the uncoupled state of the WT-MC 4 R ( Table 1 ). The second groups of receptors lack completely or have a significant reduction in their Fig. 3 . Identification of the Cys residue responsible for cross-linking the wild type MC 4 R in the presence of CuP. Cys residues were mutated in turn to alanine, and stably expressed in HEK-293 cells. Membranes were prepared for each mutant and treated with and without 5 mM copper1-10-phenanthroline (CuP) at 22°C for 1 h. Western blotting was performed using the antibody to the MC 4 R (Chemicon). Molecular mass is denoted in kDa. The mutant c-Myc-C84A-MC 4 R did not form a disulphide bond. The experiment was repeated on 3 occasions. -terminus  84  TM2  130  TM3  138  TM3  172  TM4  177  TM4  196  TM5  256  TM6  271  ECLIII  277  ECLIII  279  ECLIII  293  TM7  318 C-terminus 319 C-terminus 326 C-terminus .07, 7.54±0.04 and 7.53±0.12 respectively), illustrating that the dysfunctional-binding receptors were not perturbing the ligand binding characteristics of the C318 mutant. Whatever the detailed molecular mechanism of this effect, it is clear that cross-talk occurs between the two-receptor monomers which have effectively retained their ability to assume the R* state.
Discussion
The work presented here, shown through Western blotting, immuno-purification, cross-linking techniques and agonist activity studies, demonstrates the existence of an MC 4 R homo-dimer in cells stably expressing the receptor. Homo-dimer formation is consistent with sandwich enzyme-linked immunosorbent assays and fluorescence energy transfer studies [29, 30] . The dimer can be covalently cross-linked though disulphide bond formation under oxidizing conditions. Mutagenesis studies indicate that only the wild type residue Cys84, in near proximity to the cytoplasmic surface of TM2, undergoes cross-linking. The implication of this is that the homo-dimer has an interface in or very near TM2, albeit that Cys84 may not be intimately critical to the interaction since mutation to alanine does not perturb dimer formation. However, the two cysteine residues are sufficiently close that cross-links form in an oxidizing environment without the intervention of a cross-bridge. The \S\S-cross-linked form of the WT-MC 4 R immunopurified with the C84A-MC 4 R variant suggesting that an oligomeric complex was formed between the WT-MC 4 R dimer and the C84A-MC 4 R mutant. It is most unlikely that the WT-MC 4 R would cross-link preferentially with another \SH on the C84A-MC 4 R since this would imply considerable conformational re-arrangements in a dimer species, which is very stable even when the Cys84 residues are replaced with an alanine. Moreover, we detected no evidence that there was any change in the functional characteristics of the mixed species or any cross-linking with the C84A mutant alone as might be expected if conformational changes were occurring. Therefore, the data suggest these dimers can also form higher order oligomers, presumably involving a different interface such as those identified in other GPCR dimeric complexes. In the case of rhodopsin and the D 2 dopamine receptor, the dimer interface is thought to be located on TM4 [21, [24] [25] [26] or H8 [27] , however a recent crystal structure of the opioid receptor has elucidated that TM5-TM6 is important [28] .
Both the WT-MC 4 R and the TM2 mutant C84A-MC 4 R were active and capable of interaction with the G-protein (Fig. 5) ; illustrated through co-immuno-purification studies. However, cross-linking through this Cysteine residue was completely abolished by incubation with 1 mM GTPγS (agonist stimulated) at room temperature (and in a dose dependent manner), which uncoupled the Gα-protein from the receptor in a similar dose effect (Fig. 7) . However, when the receptor is devoid of the G-protein, it still remains oligomeric as demonstrated through Co-IP (Fig. 1) . This indicates that the receptor is a constitutive dimer, but the conformation of the interaction site (and potentially of other regions in the whole protein) alters when coupled with the G-protein. It is not yet clear if this dynamic process involves changes in higher levels of oligomerization but the functional consequences are related to the occupancy of the oligomeric complex.
In the coupled form (G-protein associated), MC 4 R exists as a dimer (TM2:TM2). When in the uncoupled state, the receptor remains a dimer (with a somewhat lower affinity for the agonist but not the antagonist). Using two methods of quantifying occupancy (competition binding [ This suggests that when in the G-protein coupled form, the receptor appears to exhibit behavior akin to negative co-operativity. Perhaps the agonist binds to only one of the monomers with high affinity. Kopachuk and colleges, through kinetic studies, have suggested that MC 4 R binds NDP-MSH with two tandemly arranged, interconnected, mutually dependent binding sites [31, 32] . Additionally, only one of the NDP-MSH units dissociates from the dimer; the other has a very slow off rate. Here we have shown that MC 4 R, when in the G-protein bound state, exhibits occupancy for NDP-MSH lower than when unbound. Western blotting demonstrated that the level of G-protein association with the receptor corresponds to the levels of binding and cross-linking. Additionally, the same concentrations of other nucleotides, including GTP, GDP and ATP bring about a similar, though less pronounced effect as GTPγS, implying a clear G-protein-mediated effect. It is possible that the G-protein is rather tightly associated with the receptor in the endogenous situation and that the coupled and uncoupled conformations have similar affinity values. Negative co-operativity between the G-protein and the receptor would allow more subtle modulation of the receptor. When the dimer changes conformation to the uncoupled state (as demonstrated by the cross-linking results), the B max values for both the agonist and the antagonist increase. Whether this is as simple as negative co-operativity within the dimeric complex or related to a more extended oligomeric array will require further pharmacological investigation.
The native, non-activated state of the receptor is in a conformation that facilitates cross-link formation. When activated, the resulting conformation state (associated with uncoupling) is not able to cross-link, presumably due to an altered positioning of Cys84. Thus, it appears that the MC 4 R protein is in a dynamic and sensitive state as illustrated by its structural and functional characteristics and by the presence of both a native agonist and inverse agonist.
Our studies show that mutation of C318A, located in the C-terminal region, resulted in a loss of the ability to increase cAMP production, but the binding of the agonist as assessed using competition studies was unaffected. The mutant receptors D126C and M292C showed no detectable binding using competition studies and NDP-MSH potency was significantly reduced or abolished altogether. When the C318A mutant was co-expressed with the MC 4 R mutants D126C or M292C, near normal levels of activation were restored. Neither complex caused any significant change in K d for agonist compared to the C318A mutant alone. It is plausible that the mutation C318A affects G-protein interaction with the receptor rather than changing the active conformation of the receptor so that D126C allows full activation.
Accumulating data have suggested that receptors form at least dimers [40] and that there can be a level of co-operativity within the complex. Again, only one site of action has been assumed in the allosteric modulation by the G-protein of the R* state [41] . However, the possibility of more than one-or-more different sites of interaction should not be ignored. A series of competition experiments and saturation curves have introduced a role for co-operativity, with ligand binding oscillating between two states of cross-talk [42] . Co-operativity was terminated by dissociation of one of the proteins or independent binding of ligand by the receptor. However, this model may over-simplify the system as it does not take into account different interactions between the receptor CRE-luciferase assays were used to identify receptor activity. Data are expressed as pEC 50 ± SEM. The number of independent experiments is shown in brackets. Significant differences were evaluated using the Student t test, and comparisons were made between single and dual expressed membranes (*p b 0.05) and WT-MC 4 R vs WT-MC 4 R expressed with mutant ( §p b 0.05). NA = no activation. NB = no binding. and the G-protein, including the ability to interact with more than one type of G-protein [43] . There is also the possibility of domain swapping as postulated previously [44] [45] [46] but this seems less likely since these are essentially the same monomers varying only in a single mutation in quite different regions of the molecule. However the recent emerging documentation of biased ligand signaling through multi-state receptor conformations [44, 45] , may provide insights into the different levels of occupancy for the agonist with regards to the dimeric conformation.
Conclusion
The data presented here demonstrate that the MC 4 R forms a constitutive dimer (and possibly even a higher order complex) which exists in different conformations depending on association with the G-protein and the agonist i.e. the oligomeric state is both stable and conformationally dynamic. At least one interaction is made between the receptor sub-units; this allows disulphide cross-linking at the cytoplasmic surface of TM2 under oxidizing conditions. This interface reflects the G-protein coupled state, and the dimeric species. This state appears to regulate the ligand occupancy of the receptor. Further studies indicate that there is cross-talk between the monomers such that binding of a single ligand to one monomer can induce the active state in the other. There are, therefore, high levels of modulation not only between two receptor sub-units in a dimeric complex but also between the G-protein and the receptor.
